Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib.

[1]  A. Shaw,et al.  Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine , 2015, Clinical Cancer Research.

[2]  Aleksandra Markovets,et al.  Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M , 2015, Nature Medicine.

[3]  L. Sequist,et al.  Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. , 2015, The Lancet. Oncology.

[4]  G. Getz,et al.  RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer , 2015, Nature Communications.

[5]  F. Tanaka,et al.  In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line , 2015, Cancer science.

[6]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[7]  P. Dartevelle,et al.  Small-Cell Carcinoma in the Setting of Pulmonary Adenocarcinoma: New Insights in the Era of Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  Y. Ichinose,et al.  An extremely rare case of small-cell lung cancer harboring variant 2 of the EML4-ALK fusion gene. , 2013, Lung cancer.

[9]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[10]  Y. Ichinose,et al.  First case of combined small-cell lung cancer with adenocarcinoma harboring EML4-ALK fusion and an exon 19 EGFR mutation in each histological component. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  K. Cibulskis,et al.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.

[12]  Hiroshi Sakamoto,et al.  CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. , 2011, Cancer cell.

[13]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[14]  M. Ladanyi,et al.  EGFR mutations in small-cell lung cancers in patients who have never smoked. , 2006, The New England journal of medicine.

[15]  A. Berns,et al.  Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. , 2003, Cancer cell.

[16]  N. Tommerup,et al.  Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma. , 1997, Proceedings of the National Academy of Sciences of the United States of America.